Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial
Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment
U.S. Forging a Healthier Oceania Through Trump Administration's America First Global Health Strategy Through Bilateral Health Memorandum of Understanding with Papua New Guinea - U.S. Embassy & Consulates in China